WUXI BIO has been selected for the Dow Jones Sustainability Index for two consecutive years, ranking among the top.
For the second consecutive year, recognized in the Dow Jones Sustainability Index, demonstrating leadership in sustainable development. Leading the development of green biopharmaceuticals, technological innovation empowers a healthy future. Shanghai, January 2, 2025 / PR Newswire / -- WUXI BIO, a global leading contract research, development, and manufacturing (CRDMO) service company, announced that due to its unwavering efforts and outstanding achievements in promoting sustainable development, the company has been included in the 2024 Dow Jones Sustainability Index (DJSI) and ranks among the top in the Industry. DJSI provides investors with.
WuXi Biologics Ranks Top in 2024 Dow Jones Sustainability Indices for Second Consecutive Year
Minsheng Securities: Triple resonance moving upwards, focusing on pharmaceutical innovation and Consumer in 2025.
Looking ahead to 2025, there is a bullish outlook on the upward resonance of policy, fundamentals, and market sentiment, comprehensively optimistic about the pharmaceutical sector, with a focus on high-quality assets in pharmaceutical innovation and consumer sectors.
Hong Kong stocks are moving | CRO Concept stocks rose broadly in the morning, with most companies' overseas Business improving on a quarter-on-quarter basis. Institutions are Bullish on the Industry entering a stable growth phase.
CRO Concept stocks generally rose in the morning. As of the time of writing, Asymchem Laboratories (06821) rose by 4.16%, trading at 52.6 Hong Kong dollars; WUXI APPTEC (02359) rose by 3.53%, trading at 55.8 Hong Kong dollars; PHARMARON (03759) rose by 3.06%, trading at 14.14 Hong Kong dollars.
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
WuXi Biologics Included in UNGC 20 Case Examples of Sustainable Development for 20 Years Collection
Leading Green CRDMO Driven by Innovation for a Healthier Future Offering End-to-end Green Biologics Solutions for the Entire Industry SHANGHAI, Dec. 12, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio"
